Type of security: Stock
Sector: Health Care
Industry: Medical/Dental Instruments
The data is delayed by 15 minutes.
Description: Cerus Corporation, together with its subsidiary, Cerus Europe B.V., operates as a biomedical products company in Europe, the Commonwealth of Independent States, and the Middle East. The company develops and commercializes the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System is based on its proprietary technology for controlling biological replication and designed to target and inactivate blood-borne pathogens, including viruses, bacteria, and parasites, as well as potentially harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, and red blood cell transfusion products. The company?s INTERCEPT Blood System for platelets is designed to inactivate blood-borne pathogens in platelets donated for transfusion; INTERCEPT Blood System for plasma is designed to inactivate blood-borne pathogens in plasma donated for transfusion; and INTERCEPT Blood System for red blood cells is designed to inactivate blood-borne pathogens in red blood cells donated for tran
See how to gain 20% in 14 sec with TrendsInvesting
|Shares Outstanding||EPS||-0.63||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||-10.57%||Sales Growth - Q/Q||-19.77%||P/E||-3.54|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-33.51%||ROE||-43.65%||ROI||-39.88%|
|Current Ratio||5.99||Quick Ratio||5.29||Long Term Debt/Equity||0.08||Debt Ratio||0.21|
|Gross Margin||40%||Operating Margin||-137.01%||Net Profit Margin||-132.42%||Dividend Payout Ratio|
|Cash From Financing Activities||76.5 M||Cash From Investing Activities||-65.59 M||Cash From Operating Activities||-15.75 M||Gross Profit||2.98 M|
|Net Profit||-9.46 M||Operating Profit||-14.37 M||Total Assets||143.22 M||Total Current Assets||136.42 M|
|Total Current Liabilities||22.76 M||Total Debt||9.88 M||Total Liabilities||33.29 M||Total Revenue||7.69 M|
|High 52 week||6.85||Low 52 week||4.09||Last close||4.34||Last change||0.46%|
|RSI||49.67||Average true range||0.21||Beta||0.97||Volume||739.37 K|
|Simple moving average 20 days||-0.37%||Simple moving average 50 days||-6.27%||Simple moving average 200 days||-19.92%|
|Performance Week||0.7%||Performance Month||-1.59%||Performance Quart||-19.63%||Performance Half||-15.07%|
|Performance Year||-14.9%||Performance Year-to-date||-14.4%||Volatility daily||2.77%||Volatility weekly||6.19%|
|Volatility monthly||12.68%||Volatility yearly||43.91%||Relative Volume||436.07%||Average Volume||882.94 K|
|New High||New Low|
2020-05-27 12:00:04 | Cerus CERS Upgraded to Buy: What Does It Mean for the Stock?
2020-05-06 07:33:36 | Cerus Corporation CERS Q1 2020 Earnings Call Transcript
2020-05-06 02:28:57 | Edited Transcript of CERS earnings conference call or presentation 5-May-20 8:30pm GMT
2020-05-05 18:45:10 | Cerus CERS Reports Q1 Loss, Tops Revenue Estimates
2020-05-05 16:01:00 | Cerus Corporation Announces First Quarter 2020 Results
2020-04-29 10:05:02 | Moving Average Crossover Alert: Cerus
2020-04-28 12:34:04 | Will Cerus CERS Report Negative Earnings Next Week? What You Should Know
2020-04-24 08:30:00 | Cerus Corporation to Release First Quarter 2020 Financial Results on May 5, 2020
2020-04-23 11:43:03 | Cerus Corporation CERS Shares March Higher, Can It Continue?
2020-04-07 08:40:07 | Introducing Cerus NASDAQ:CERS, The Stock That Dropped 26% In The Last Year
2020-04-06 08:30:00 | Cerus Corporation Provides Update on COVID-19 Related Activities
2020-03-26 08:30:00 | Cerus Forms Group to Research Optimal Production of COVID-19 Convalescent Plasma
2020-03-02 16:10:00 | Cerus Corporation Announces Strategic Organizational Changes
2020-02-25 15:25:00 | 18 Medical Stocks To Watch Amid The Coronavirus Outbreak
2020-02-25 08:30:00 | Cerus Corporation to Participate in Upcoming Investor Conferences
2020-02-22 07:58:46 | Cerus Corporation Just Reported, And Analysts Assigned A US$8.25 Price Target
2020-02-21 21:28:29 | Edited Transcript of CERS earnings conference call or presentation 20-Feb-20 9:30pm GMT
2020-02-20 16:01:00 | Cerus Corporation Announces Record Fourth Quarter and Full Year 2019 Financial Results
2020-01-29 09:00:00 | Cerus Corporation Announces Pricing of Upsized Public Offering of Common Stock
2020-01-28 16:01:00 | Cerus Corporation Announces Public Offering of Common Stock
2020-01-23 13:02:09 | 13 Coronavirus-Related Stocks To Watch Amid Wuhan Outbreak
2019-12-30 14:08:49 | Is Cerus NASDAQ:CERS Using Debt Sensibly?
2019-12-16 16:38:51 | Cerus Corporation CERS: Are Hedge Funds Right About This Stock?
2019-11-13 08:30:00 | Cerus Corporation to Present at the Stifel 2019 Healthcare Conference
2019-11-12 06:45:12 | How Should Investors React To Cerus Corporation's NASDAQ:CERS CEO Pay?
2019-11-08 08:30:00 | Cerus Corporation to Present at the Stephens Nashville Investment Conference
2019-11-01 09:34:11 | Were Hedge Funds Right About Cashing Out Of Cerus Corporation CERS?
2019-10-31 12:41:23 | Edited Transcript of CERS earnings conference call or presentation 30-Oct-19 8:30pm GMT
2019-10-30 18:45:10 | Cerus CERS Reports Q3 Loss, Tops Revenue Estimates
2019-10-30 16:01:00 | Cerus Corporation Announces Third Quarter 2019 Results
2019-10-23 10:34:02 | Will Cerus CERS Report Negative Earnings Next Week? What You Should Know
2019-10-18 08:30:00 | Cerus Corporation Announces Schedule of Presentations at the 2019 AABB Annual Meeting
2019-10-13 09:36:37 | How Much Are Cerus Corporation NASDAQ:CERS Insiders Taking Off The Table?